Publications by authors named "Emmanuel Oguda"
Article Synopsis
- African children with severe malaria have high death rates, particularly within the first 24 hours of hospital admission, largely due to lactic acidosis caused by parasite sequestration.
- Sevuparin, a heparin-like drug, may improve outcomes by preventing merozoite invasion and enhancing blood flow in infected individuals when administered early during admission.
- A Phase I trial in Kenya and Zambia will evaluate the safety and optimal dosing of sevuparin in children with severe malaria and lactic acidosis, with results expected to inform future Phase II trials.
Background: Severe pneumonia in African children results in poor long-term outcomes (deaths/readmissions) with undernutrition as a key risk factor. We hypothesised additional energy/protein-rich Ready-to-Use Therapeutic Foods (RUTF) would meet additional nutritional requirements and improve outcomes.
Methods: COAST-Nutrition was an open-label Phase 2 randomised controlled trial in children (aged 6 months-12 years) hospitalised with severe pneumonia (and hypoxaemia, SpO <92%) in Mbale, Soroti, Jinja, Masaka Regional Referral Hospitals, Uganda and Kilifi County Hospital, Kenya (ISRCTN10829073 (registered 6th June 2018) PACTR202106635355751 (registered 2nd June 2021)).